India’s New Weapon Against Superbugs: How Cefepime + Zidebactam Defeats Resistant Bacteria
Discovered and developed in India by Wockhardt.
India has developed a new antibiotic Zaynich[Cefepime + Zidebactam] to help fight superbugs. The therapy has also received approval from the US FDA, marking an important step in the global battle against antibiotic resistance.
When harmful bacteria enter the body, our white blood cells try to destroy them. To survive, some bacteria create a protective outer wall that acts like a shield against the body’s defenses. Antibiotics are designed to break this protective wall and kill the bacteria.
But bacteria are evolving. Some have developed an extra layer of defense in the form of enzymes that act like guards standing in front of the wall. These enzymes destroy or deactivate the antibiotic before it can reach its target. As a result, the bacteria survive, multiply, and become difficult to treat—earning the name superbugs.
Cefepime + Zidebactam works through a powerful dual-action approach against resistant bacteria. Cefepime attacks the bacteria by blocking the proteins responsible for building the bacterial cell wall—almost like handcuffing the workers constructing the wall. Without a strong wall, the bacteria become weak and die.
At the same time, Zidebactam acts as a protector and enhancer. It binds to key bacterial targets and also helps overcome the enzymes produced by resistant bacteria that would normally destroy antibiotics before they can act. By attacking both the wall-building process and the bacteria’s defense mechanisms, this combination offers a promising weapon against difficult-to-treat superbugs.
Zaynich treatment refers to an intravenous (IV) antibiotic therapy that combines cefepime + zidebactam. It is designed to treat certain difficult-to-treat bacterial infections caused by resistant (superbug) Gram-negative bacteria.
At present, the approved indication is:
- Complicated urinary tract infections (cUTI)
- Including kidney infections (pyelonephritis)
- For infections caused by susceptible bacteria such as E. coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, and Pseudomonas aeruginosa
No comments:
Post a Comment